To assess the immunological cross-reactivity of the monobactam antibiotic aztreonam (AZ), rabbits were immunized with protein conjugates of benzylpenicillin, cephalothin (CEPH), and AZ. The resulting antibenzylpenicilloyl (BPO) and anti-CEPH rabbit antibodies showed negligible cross-reactivity with AZ conjugated to human serum albumin (AZ-HSA), whereas anti-AZ showed negligible cross-reactivity with BPO-HSA and CEPH-HSA. Unlike benzylpenicillin and CEPH, unconjugated AZ was as effective as AZ conjugated to epsilon aminocaproic acid (AZ-EACA) in inhibiting the binding of homologous antibody. Studies with various analogs of AZ confirmed that immunoglobulin G (IgG) anti-AZ was entirely side-chain specific. The inhibition of the binding of human IgE anti-penicilloyl to BPO-HSA was studied in the presence of AZ-EACA, BPO-formyl lysine, and CEPH-EACA. Whereas CEPH-EACA displayed 3% crossreactivity with BPO-lysine, AZ-EACA showed little or no cross-reactivity (<<0.9%). To assess the immunogenicity of AZ in humans, IgE and IgG antibodies were measured in sera from 36 healthy male volunteers receiving 0.5 or 1 g intravenously or intramuscularly every 8 h for 7 days. None of the subjects had detectable preexisting IgE reactive with AZ or demonstrated an IgE response to antibiotic administration. Four subjects gave evidence for naturally occurring IgG cross-reactive with AZ, but only one subject demonstrated a rise in IgG levels after exposure to AZ. This anti-AZ IgG did not cross-react with BPO or CEPH conjugates of bovine thyroglobulin and was completely side-chain specific. These studies suggest that AZ displays very low immunological cross-reactivity with other
Penicillin and cephalosporin antibiotics have consistently proven to be immunologically cross-reactive to varying degrees because of similar nuclear configurations despite marked differences in side-chain composition (2, 3, 6) . This cross-reactivity and the immunogenicity (ability to stimulate an immune response) of available penicillins have hampered the administration of these antibiotics. Aztreonam (AZ) (SQ 26,776; formerly azthreonam) is a member of a newly discovered category of 1-lactam antibiotics, the monobactams, characterized by a monocyclic (as opposed to bicyclic penicillins and cephalosporins) ,B-lactam ring structure (10) . Unlike naturally occurring monobactams made by bacteria, AZ is completely synthetic. AZ has potent bactericidal activity against aerobic gram-negative bacteria (9) and has been used successfully in early clinical trials to treat serious infections due to gram-negative bacteria. Because of the therapeutic potential of AZ and the clinical importance of cross-sensitivity among P-lactam antibiotics, studies have been undertaken to explore the potential for immunological cross-reactivity among AZ, benzylpenicillin, and cephalothin (CEPH). In addition, the immunogenicity of AZ administered in multiple doses to healthy male volunteers was investigated.
MATERIALS AND METHODS Reagents. The major antigenic determinant of penicillin, toward which the immune response against this antibiotic is largely directed, is the penicilloyl moiety. This determinant is formed by simple hydrolysis of the ,B-lactam ring, with formation of an amide linkage predominantly with epsilon amino groups of lysine residues in plasma-or membranebound proteins. In analogous fashion, the cephalosporyl * Corresponding author. determinant is the principal immunogen for cephalosporin antibiotics, though antibodies specific for some cephalosporin side chains have occasionally been observed (2, 4 RAST assay. The radioallergosorbent (RAST) assay employed was an agarose-based (solid phase) immunoradiometric assay developed and standardized for the measurement of drug-specific rabbit antibodies. Conjugates of AZ-HSA were covalently bound to agarose beads by a cyanogen bromide technique. The immunoabsorbent had been previously standardized with rabbit antisera and was found to be acceptable in terms of specificity and low nonspecific bind-ing. The assay was performed as follows: 0.5 ml of a 1% (vol/vol) AZ-HSA-agarose suspension was placed in a tube (12 by 75 mm) to which was added 0.1 ml of serum previously diluted 1:40 in assay buffer (physiological-buffered saline containing 0.1% HSA and 0.3% Tween 20). Further dilutions were made in a 1:40 dilution of normal human serum. The standard curve was prepared with a rabbit antiserum raised against conjugates of AZ-BTG. Dilutions of this rabbit serum beyond 1:40 were made in a 1:40 dilution of normal rabbit serum. The rabbit antiserum and all test sera were preabsorbed to remove naturally occurring antiagarose antibodies, employing an overnight incubation with 5% (vol/vol) uncoupled agarose. Tubes containing immunoabsorbent and standard or test serum were rotated orbitally at a 450 inclination at room temperature for 18 to 22 h. Tubes were then washed three times with 2 ml of assay buffer. Staphylococcus protein A previously radioiodinated with 1251, for which both rabbit and human immunoglobulin G (IgG) have high affinity, then was added to the residual washed immunoabsorbent in sufficient excess to occupy all Staphylococcus protein A-binding sites on IgG molecules. After a second overnight incubation with rotation, the assay tubes were washed again four times with 2 ml of assay buffer. Radioactivity in all tubes was counted in an automatic gamma counter. Results were expressed as net counts per minute bound (total counts per minute minus negative serum control). When positive, the quantity of antibody was determined by interpolation from the standard curve. The Staphylococcus protein A radioimmunoassay was sensitive to 500 ng of IgG antibody per ml of serum.
Each serum sample was evaluated in triplicate in one or more experiments. Student's paired t tests were employed to determine which sera contained significantly more drugspecific antibodies than negative sera controls. All sera that were determined in one or more assays to have significantly more antibody than the control were studied further in an inhibition assay. In this assay, the binding power of each serum sample was compared in the presence and absence of a soluble monovalent inhibitor, AZ-EACA (AZ covalently linked to EACA). Student's t tests were used to determine statistically significant inhibition.
A similar RAST assay was performed by using AZ-BTG (instead of AZ-HSA) coupled to agarose by a standard cyanogen bromide technique and radiolabeled rabbit antiIgE (specific for the Fc portion of the IgE molecule), instead of Staphylococcus protein A. This assay permitted the detection of 1 ng of human IgE per ml directed against AZ.
Radioimmunoprecipitation assay. HSA was radioiodinated with 125I by a standard chloramine T method. After this procedure, AZ was hydrolyzed onto epsilon amino groups of lysine residues on the radioiodinated HSA, employing alkaline conditions (pH 10.0, 30 min, 25°C). Excess rabbit antiserum specific for AZ-BTG was used to establish that the drug-specific immunoreactivity of the 125I-AZ-HSA was <90%.
This radiotracer was employed in a radioimmunoprecipitation assay that, in analogous systems in the same laboratory, was sensitive to ca. 10 ng of drug-specific IgG per ml. Positive standards (serum no. 448-619 from this study) and negative controls were run in each assay. Because the negative controls displayed a considerable range in this assay, all apparently positive results were followed-up by specific inhibition studies, which provided the ultimate criterion for the presence of AZ-specific IgG. For the latter studies, the inhibition of precipitated 125I-AZ-HSA by 10 
RESULTS
Cross-reactivity studies with rabbit antisera. The results of studies of the cross-reactivity of antibodies raised in rabbits against the three P-lactam drug-protein conjugates are shown in Fig. 1 . Figure la displays Cross-reactivity of human IgE anti-penicilloyl antibodies. Serum samples were obtained from three penicillin-allergic human subjects having positive IgE-dependent skin tests to BPO-polylysine. Suitable dilutions were chosen to give comparable levels of binding of IgE anti-penicilloyl antibody in the RAST assay. Inhibition studies were performed with homologous and heterologous polyvalent and monovalent drug conjugates as well as the unconjugated drug. Results with all three sera were comparable and are summarized in Table 1 . A representative inhibition study is shown in Fig. 3 .
Human IgE anti-penicilloyl antibody was very weakly cross-reactive (<<0.001 to <<0.9%) with AZ conjugates (Table 1) . As expected, CEPH conjugates were cross-reactive at higher levels from 0.04 to 3%. Similar results were obtained with inhibition studies by using three sera with high titers of IgG anti-penicilloyl antibody in the radioimmunoprecipitation assay (Table 1) .
Primary immunogenicity of AZ in humans. Results of the RAST and radioimmunoprecipitation assays revealed that naturally occurring IgE cross-reactive with AZ was absent from the predose (control) sera of all study subjects, and there was no IgE response after the parenteral administration of AZ. In contrast, by using the radioimmunoprecipitation assay, predose sera from 4 of 36 subjects displayed small amounts of AZ-inhibitable binding activity, which may Figure lc indicates the results with rabbit anti-AZ antisera. Cross-reactivity with the penicillin and cephalosporin conjugates tested was minimal (<0.001%).
Finally, it was observed that free AZ was equally effective on a molar basis with AZ-EACA in inhibiting anti-AZ antibody binding to the AZ-HSA immunoabsorbent (Fig. 2) . have represented low levels of naturally occurring IgG that was cross-reactive for AZ. This preexisting cross-reacting antibody was boosted by AZ exposure in only one of the four subjects. The counts per minute of 125I-AZ-HSA that was bound by the pretreatment sera and inhibitable by AZ-BTG was 148 cpm greater than negative control sera, which averaged 547 ± 26 cpm (mean ± standard error of the mean, n = 4). This net inhibitable binding was unchanged at 168 h but rose to 312 cpm above control at day 14 and to 974 cpm above background at day 21. The anti-AZ IgG was not crossreactive with BPO-BTG or CEPH-BTG. However, free AZ and AZ-BTG were equally effective as inhibitors. Dialysis of sera collected from human subjects did not affect the observed result, indicating that free AZ or metabolites did not interfere with the assay. ies. Inhibition studies with both prepared rabbit antisera and human sera from penicillin-allergic patients indicate that anti-penicilloyl antibodies bind poorly, if at all, with AZ and its conjugates. The expected cross-reactivity with CEPH was demonstrated, indicating that the experimental system is capable of identifying partial cross-reactivity. Based on these limited studies, it is reasonable to anticipate that at least those penicillin-allergic patients with a major determinant (penicilloyl) allergy may receive treatment with monobactam antibiotics with little likelihood of cross-allergenicity. This possibility is very attractive clinically, because penicillin and cephalosporin hypersensitivity generally contraindicate the use of all currently available ,-lactam antibiotics.
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The low incidence (O to 3%) of a drug-specific antibody response atnong humans receiving full therapeutic doses of AZ suggests that AZ is only weakly immunogenic, compared with older P-lactam antibiotics. Ultimately, however, multiple courses of therapy with AZ will have to be examined to establish the absolute immunogenicity of AZ, because a secondary antibody response may not occur upon first exposure to the drug. Furthermore, it remains to be shown that the P-lactam hydrolysis product of AZ represents the immunodominant conformation of the drug. Other haptenic conformations of the drug may also prove to be immunogenic in some or all subjects receiving the antibiotic.
This study provides the first demonstration of a human IgG antibody response to parenterally administered AZ. The greatest rise in serum IgG levels occurred 2 weeks after the last AZ dose. It is noteworthy that this IgG antibody to AZ did not cross-react with the major penicillin or cephalosporin antigenic determinants, a confirmation of findings obtained with sera from AZ-immutnized rabbits. Low levels of naturally occurring IgG cross-reactive with AZ were seen in 4 of 36 subjects not previously exposed to AZ, but these levels were generally not boosted by AZ exposure and are, therefore, likely to be insignificant with regard to the potential for mediating drug-induced immunopathological events; The origin of these naturally occurring AZ-binding antibodies remains unexplained.
If future studies confirm that AZ is poorly cross-reactive with other 1-lactam antibiotics, AZ and similar monobactams may be of particular value for patients who have demonstrated sensitivity to penicillins or cephalosporins. 'If, in addition, its immunogenicity proves to be weak, the long search for a relatively non-allergenic 1-lactam antibiotic may at last come to fruition. Clinical studies to evaluate these two possibilities further are now in progress.
